The Angiotensin II Type 1—Receptor Blocker Candesartan Increases Cerebral Blood Flow, Reduces Infarct Size, and Improves Neurologic Outcome after Transient Cerebral Ischemia in Rats
暂无分享,去创建一个
M. Forsting | A. Doerfler | G. Heusch | T. Engelhorn | R. Schulz | Sophia Goerike | Christine Okorn | C. Okorn
[1] W. Kernan. Re: Evaluation of acute candesartan cilexetil therapy in stroke survivors. , 2003, Stroke.
[2] H. Diener,et al. The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors , 2003, Stroke.
[3] N. Kobayashi,et al. Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats. , 2001, Atherosclerosis.
[4] T. Unger. Inhibiting Renin-Angiotensin in the Brain: the Possible Therapeutic Implications , 2001, Blood pressure. Supplement.
[5] J. Saavedra,et al. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. , 2000, Stroke.
[6] K. Hoe,et al. Chronic peripheral administration of the angiotensin II AT1 receptor antagonist Candesartan blocks brain AT1 receptors , 2000, Brain Research.
[7] C. Sotak,et al. Temporal evolution of ischemic injury evaluated with diffusion-, perfusion-, and T2-weighted MRI , 2000, Neurology.
[8] JurajCulman,et al. Blockade of Central Angiotensin AT1 Receptors Improves Neurological Outcome and Reduces Expression of AP-1 Transcription Factors After Focal Brain Ischemia in Rats , 1999 .
[9] C. Beaulieu,et al. Decompressive craniectomy, reperfusion, or a combination for early treatment of acute "malignant" cerebral hemispheric stroke in rats? Potential mechanisms studied by MRI. , 1999, Stroke.
[10] G. Böhme,et al. Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury , 1999, British journal of pharmacology.
[11] B. Mayer,et al. Normalizing the expression of nitric oxide synthase by low-dose AT1 receptor antagonism parallels improved vascular morphology in hypertensive rats. , 1999, Journal of the American Society of Nephrology : JASN.
[12] G. Heusch,et al. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. , 1998, Journal of the American College of Cardiology.
[13] J. Saavedra,et al. The angiotensin AT1 receptor antagonist CV-11974 regulates cerebral blood flow and brain angiotensin AT1 receptor expression , 1998, Basic Research in Cardiology.
[14] C. Iadecola,et al. Delayed Treatment with Aminoguanidine Decreases Focal Cerebral Ischemic Damage and Enhances Neurologic Recovery in Rats , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] D C Rogers,et al. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? , 1998, Trends in pharmacological sciences.
[16] Fangyi Zhang,et al. Delayed Reduction of Ischemic Brain Injury and Neurological Deficits in Mice Lacking the Inducible Nitric Oxide Synthase Gene , 1997, The Journal of Neuroscience.
[17] Y. Fujisawa,et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. , 1997, Clinical and experimental hypertension.
[18] W. Hacke,et al. Bolus injection of MR contrast agents: hemodynamic effects evaluated by intracerebral laser Doppler flowmetry in rats. , 1997, AJNR. American journal of neuroradiology.
[19] M. Ross,et al. Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. , 1996, Stroke.
[20] Koroshetz Wj,et al. Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.
[21] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[22] M. Kaste,et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.
[23] O. Haraldseth,et al. Perfusion and diffusion-weighted MR imaging for in vivo evaluation of treatment with U74389G in a rat stroke model. , 1995, Stroke.
[24] L. J. Chandler,et al. Angiotensin II decreases inducible nitric oxide synthase expression in rat astroglial cultures. , 1995, The American journal of physiology.
[25] M. Yokoyama,et al. Angiotensin II inhibits cytokine-stimulated inducible nitric oxide synthase expression in vascular smooth muscle cells. , 1994, The Journal of biological chemistry.
[26] P. Meredith. Dihydropyridines versus other agents in the treatment of hypertension in the elderly. Part 3: Safety, efficacy, tolerability and duration of action , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[27] S. Ibayashi,et al. Angiotensin Converting Enzyme Inhibitors Attenuate Ischemic Brain Metabolism in Hypertensive Rats , 1993, Stroke.
[28] K. Kubo,et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl , 1993, The Journal of pharmacology and experimental therapeutics.
[29] C. Stier,et al. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[30] Teng-Nan Lin,et al. Effect of Brain Edema on Infarct Volume in a Focal Cerebral Ischemia Model in Rats , 1993, Stroke.
[31] M. Kaste,et al. The European Cooperative Acute Stroke Study (ECASS) , 1993 .
[32] J. Laragh,et al. Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. , 1992, Journal of hypertension.
[33] A. Betz,et al. Middle cerebral artery occlusion in rats: a neurological and pathological evaluation of a reproducible model. , 1992, Neurosurgery.
[34] G. Heusch,et al. Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery. A model of short-term hibernation. , 1992, Circulation research.
[35] M D Ginsberg,et al. The Significance of Brain Temperature in Focal Cerebral Ischemia: Histopathological Consequences of Middle Cerebral Artery Occlusion in the Rat , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[36] W. Pulsinelli,et al. Temporal thresholds for neocortical infarction in rats subjected to reversible focal cerebral ischemia. , 1991, Stroke.
[37] W. Hoffman,et al. Captopril improves neurologic outcome from incomplete cerebral ischemia in rats. , 1991, Stroke.
[38] U. Dirnagl,et al. Continuous Measurement of Cerebral Cortical Blood Flow by Laser—Doppler Flowmetry in a Rat Stroke Model , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[39] P. Weinstein,et al. Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.
[40] L. Pitts,et al. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. , 1986, Stroke.
[41] L. Pitts,et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. , 1986, Stroke.
[42] S. Papson,et al. “Model” , 1981 .
[43] H. Handa,et al. Pathogenetic Similarity of Strokes in Stroke‐Prone Spontaneously Hypertensive Rats and Humans , 1976, Stroke.